|
1
|
Scheidegger R, Wong ET and Alsop DC:
Contributors to contrast between glioma and brain tissue in
chemical exchange saturation transfer sensitive imaging at 3Tesla.
Neuroimage. 99:256–268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanai N, Chang S and Berger MS: Low-grade
gliomas in adults. J Neurosurg. 115:948–965. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tökés AM, Szász AM, Geszti F, et al:
Expression of proliferation markers Ki67, cyclin A, geminin and
aurora-kinase A in primary breast carcinomas and corresponding
distant metastases. J Clin Pathol. 68:274–282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bosserhoff AK: Novel biomarkers in
malignant melanoma. Clin Chim Acta. 367:28–35. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kleihues P and Cavenee WK: World Health
Organization Classification of TumoursPathology and Genetics of
Tumours of the Nervous System. IARC Press; Lyon: 2000
|
|
7
|
Biernat W: 2000 World Health Organization
classification of tumors of the nervous system. Pol J Pathol.
51:107–114. 2000.PubMed/NCBI
|
|
8
|
Thomas L, Di Stefano AL and Ducray F:
Predictive biomarkers in adult gliomas: The present and the future.
Curr Opin Oncol. 25:689–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Masuda TA, Inoue H, Sonoda H, Mine S,
Yoshikawa Y, Nakayama K, Nakayama K and Mori M: Clinical and
biological significance of S-phase kinase-associated protein 2
(Skp2) gene expression in gastric carcinoma: Modulation of
malignant phenotype by Skp2 overexpression, possibly via p27
proteolysis. Cancer Res. 62:3819–3825. 2002.PubMed/NCBI
|
|
10
|
Katsetos CD, Reginato MJ, Baas PW, et al:
Emerging microtubule targets in glioma therapy. Semin Pediatr
Neurol. 22:49–72. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He X, Huang Q, Qiu X, et al: LAP3 promotes
glioma progression by regulating proliferation, migration and
invasion of glioma cells. Int J Biol Macromol. 72:1081–1089. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takanami I: The prognostic value of
overexpression of Skp2 mRNA in non-small cell lung cancer. Oncol
Rep. 13:727–731. 2005.PubMed/NCBI
|
|
13
|
Mason WP, Maestro RD, Eisenstat D, Forsyth
P, Fulton D, Laperrière N, Macdonald D, Perry J and Thiessen B:
Canadian GBM Recommendations Committee: Canadian recommendations
for the treatment of glioblastoma multiforme. Curr Oncol.
14:110–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kamata Y, Watanabe J, Nishimura Y, Arai T,
Kawaguchi M, Hattori M, Obokata A and Kuramoto H: High expression
of skp2 correlates with poor prognosis in endometrial endometrioid
adenocarcinoma. J Cancer Res Clin Oncol. 131:591–596. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hart MG, Grant R, Garside R, Rogers G,
Somerville M and Stein K: Temozolomide for high grade glioma.
Cochrane Database Syst Rev. 4:CD0074152008.PubMed/NCBI
|
|
16
|
Mamillapalli R, Gavrilova N, Mihaylova VT,
Tsvetkov LM, Wu H, Zhang H and Sun H: Pten regulates the
ubiquitin-dependent degradation of the CDK inhibitor p27 (KIP1)
through the ubiquitin E3 ligase SCF (SKP2). Curr Biol. 11:263–267.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
von der Lehr N, Johansson S, Wu S, Bahram
F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K,
Nakayama KI, et al: The F-box protein Skp2 participates in c-Myc
proteosomal degradation and acts as a cofactor for c-Myc-regulated
transcription. Mol Cell. 11:1189–1200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hua W, Yao Y, Chu YW, et al: Phase I study
of dendritic cells pulsed with tumor stem-like cells associated
antigens against malignant glioma in recurrent patients. Zhong Hua
Shen Jing Wai Ke Za Zhi. 27:90–94. 2011.(In Chinese).
|
|
19
|
Athanassiou H, Synodinou M, Maragoudakis
E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G,
Beroukas K and Karageorgis P: Randomized phase II study of
temozolomide and radiotherapy compared with radiotherapy alone in
newly diagnosed glioblastoma multiforme. J Clin Oncol.
23:2372–2377. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang G, Ayala G, De Marzo A, Tian W,
Frolov A, Wheeler TM, Thompson TC and Harper JW: Elevated Skp2
protein expression in human prostate cancer: Association with loss
of the cyclin-dependent kinase inhibitor p27 and PTEN and with
reduced recurrence-free survival. Clin Cancer Res. 8:3419–3426.
2002.PubMed/NCBI
|
|
21
|
Dong Y, Sui L, Watanabe Y, Sugimoto K and
Tokuda M: S-phase kinase-associated protein 2 expression in
laryngeal squamous cell carcinomas and its prognostic implications.
Oncol Rep. 10:321–325. 2003.PubMed/NCBI
|
|
22
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
